FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2794062747> ?p ?o ?g. }

• W2794062747 endingPage "e0192779" @default.
• W2794062747 startingPage "e0192779" @default.
• W2794062747 abstract "Friedreich’s ataxia (FA) is an autosomal recessive neurodegenerative disorder, which results primarily from reduced expression of the mitochondrial protein frataxin. FA has an estimated prevalence of one in 50,000 in the population, making it the most common hereditary ataxia. Paradoxically, mortality arises most frequently from cardiomyopathy and cardiac failure rather than from neurological effects. Decreased high-density lipoprotein (HDL) and apolipoprotein A-I (ApoA-l) levels in the general population are associated with an increased risk of mortality from cardiomyopathy and heart failure. However, the pathophysiology of heart disease in FA is non-vascular and there are conflicting data on HDL-cholesterol in FA. Two studies have shown a decrease in HDL-cholesterol compared with controls and two have shown there was no difference between FA and controls. One also showed that there was no difference in serum Apo-A-I levels in FA when compared with controls. Using a highly specific stable isotope dilution mass spectrometry-based assay, we demonstrated a 21.6% decrease in serum ApoA-I in FA patients (134.8 mg/dL, n = 95) compared with non-affected controls (172.1 mg/dL, n = 95). This is similar to the difference in serum ApoA-I levels between non-smokers and tobacco smokers. Knockdown of frataxin by > 70% in human hepatoma HepG2 cells caused a 20% reduction in secreted ApoA-I. Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor caused a 200% increase in HMG-CoA in the control HepG2 cells with a similar increase in the frataxin knockdown HepG2 cells, back to levels found in the control cells. There was a concomitant 20% increase in secreted ApoA-I to levels found in the control cells that were treated with simvastatin. This study provides compelling evidence that ApoA-I levels are reduced in FA patients compared with controls and suggest that statin treatment would normalize the ApoA-I levels." @default.
• W2794062747 created "2018-03-29" @default.
• W2794062747 creator A5007007052 @default.
• W2794062747 creator A5007235827 @default.
• W2794062747 creator A5010542220 @default.
• W2794062747 creator A5019129225 @default.
• W2794062747 creator A5041847119 @default.
• W2794062747 creator A5045709001 @default.
• W2794062747 creator A5068779075 @default.
• W2794062747 creator A5079384190 @default.
• W2794062747 creator A5085555480 @default.
• W2794062747 date "2018-02-15" @default.
• W2794062747 modified "2023-10-17" @default.
• W2794062747 title "Low apolipoprotein A-I levels in Friedreich’s ataxia and in frataxin-deficient cells: Implications for therapy" @default.
• W2794062747 cites W1484379620 @default.
• W2794062747 cites W1584301804 @default.
• W2794062747 cites W1938553413 @default.
• W2794062747 cites W1974602677 @default.
• W2794062747 cites W1974744093 @default.
• W2794062747 cites W1977664045 @default.
• W2794062747 cites W1978039230 @default.
• W2794062747 cites W1980669182 @default.
• W2794062747 cites W1981637156 @default.
• W2794062747 cites W1993243923 @default.
• W2794062747 cites W1994874022 @default.
• W2794062747 cites W1999426108 @default.
• W2794062747 cites W2004258231 @default.
• W2794062747 cites W2009484541 @default.
• W2794062747 cites W2009516497 @default.
• W2794062747 cites W2014985882 @default.
• W2794062747 cites W2016605728 @default.
• W2794062747 cites W2020369221 @default.
• W2794062747 cites W2030713637 @default.
• W2794062747 cites W2048993312 @default.
• W2794062747 cites W2049065822 @default.
• W2794062747 cites W2091412586 @default.
• W2794062747 cites W2109063792 @default.
• W2794062747 cites W2110864849 @default.
• W2794062747 cites W2114210981 @default.
• W2794062747 cites W2120039680 @default.
• W2794062747 cites W2125078806 @default.
• W2794062747 cites W2128606426 @default.
• W2794062747 cites W2133155560 @default.
• W2794062747 cites W2134105637 @default.
• W2794062747 cites W2135552919 @default.
• W2794062747 cites W2144744813 @default.
• W2794062747 cites W2149278525 @default.
• W2794062747 cites W2152512707 @default.
• W2794062747 cites W2155629491 @default.
• W2794062747 cites W2167074069 @default.
• W2794062747 cites W2167527362 @default.
• W2794062747 cites W2174658635 @default.
• W2794062747 cites W2408317690 @default.
• W2794062747 cites W2470133543 @default.
• W2794062747 cites W2487600010 @default.
• W2794062747 cites W2528540152 @default.
• W2794062747 cites W2558361797 @default.
• W2794062747 cites W2738521389 @default.
• W2794062747 cites W4240368826 @default.
• W2794062747 doi "https://doi.org/10.1371/journal.pone.0192779" @default.
• W2794062747 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5813973" @default.
• W2794062747 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29447225" @default.
• W2794062747 hasPublicationYear "2018" @default.
• W2794062747 type Work @default.
• W2794062747 sameAs 2794062747 @default.
• W2794062747 citedByCount "12" @default.
• W2794062747 countsByYear W27940627472018 @default.
• W2794062747 countsByYear W27940627472019 @default.
• W2794062747 countsByYear W27940627472020 @default.
• W2794062747 countsByYear W27940627472021 @default.
• W2794062747 countsByYear W27940627472022 @default.
• W2794062747 countsByYear W27940627472023 @default.
• W2794062747 crossrefType "journal-article" @default.
• W2794062747 hasAuthorship W2794062747A5007007052 @default.
• W2794062747 hasAuthorship W2794062747A5007235827 @default.
• W2794062747 hasAuthorship W2794062747A5010542220 @default.
• W2794062747 hasAuthorship W2794062747A5019129225 @default.
• W2794062747 hasAuthorship W2794062747A5041847119 @default.
• W2794062747 hasAuthorship W2794062747A5045709001 @default.
• W2794062747 hasAuthorship W2794062747A5068779075 @default.
• W2794062747 hasAuthorship W2794062747A5079384190 @default.
• W2794062747 hasAuthorship W2794062747A5085555480 @default.
• W2794062747 hasBestOaLocation W27940627471 @default.
• W2794062747 hasConcept C118552586 @default.
• W2794062747 hasConcept C126322002 @default.
• W2794062747 hasConcept C134018914 @default.
• W2794062747 hasConcept C22814914 @default.
• W2794062747 hasConcept C2776329913 @default.
• W2794062747 hasConcept C2778163477 @default.
• W2794062747 hasConcept C2778198053 @default.
• W2794062747 hasConcept C2778797674 @default.
• W2794062747 hasConcept C2779314966 @default.
• W2794062747 hasConcept C2779369046 @default.
• W2794062747 hasConcept C2780072125 @default.
• W2794062747 hasConcept C2780541478 @default.
• W2794062747 hasConcept C2780906641 @default.
• W2794062747 hasConcept C2908647359 @default.
• W2794062747 hasConcept C62746215 @default.

• next